Upon administration, MCC950 inhibited fibrillar α-synuclein-induced NLRP3 activation and reduced dopaminergic neuron degeneration, aggregation of α-synuclein, and the motor symptoms experienced by the PD mice (Gordon et al., 2018). This evidence concerns the gene SNCA and Parkinson disease.